Prognostic Impact of Hyperpolypharmacy Due to Noncardiovascular Medications in Patients After Acute Decompensated Heart Failure　― Insights From the Clue of Risk Stratification in the Elderly Patients With Heart Failure (CURE-HF) Registry

Background: Hyperpolypharmacy is associated with adverse outcomes in older adults, but because literature on its association with cardiovascular (CV) outcomes after acute decompensated heart failure (ADHF) is sparse, we investigated the relationships among hyperpolypharmacy, medication class, and de...

Full description

Saved in:
Bibliographic Details
Published in:Circulation Journal 2023/12/25, Vol.88(1), pp.33-42
Main Authors: Kanai, Masafumi, Minamisawa, Masatoshi, Motoki, Hirohiko, Seko, Yuta, Kimura, Kazuhiro, Okano, Takahiro, Ueki, Yasushi, Yoshie, Koji, Kato, Tamon, Saigusa, Tatsuya, Ebisawa, Soichiro, Okada, Ayako, Ozasa, Neiko, Kato, Takao, Kuwahara, Koichiro
Format: Article
Language:English
Subjects:
Aged
Aging
Cardiovascular Agents
Heart failure
Heart Failure - drug therapy
Humans
Hyperpolypharmacy
Patient Discharge
Prognosis
Registries
Risk Assessment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Hyperpolypharmacy is associated with adverse outcomes in older adults, but because literature on its association with cardiovascular (CV) outcomes after acute decompensated heart failure (ADHF) is sparse, we investigated the relationships among hyperpolypharmacy, medication class, and death in patients with HF.Methods and Results: We evaluated the total number of medications prescribed to 884 patients at discharge following ADHF. Patients were categorized into nonpolypharmacy (
ISSN:1346-9843
1347-4820
1347-4820
DOI:10.1253/circj.CJ-22-0712